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Purpose or Objective 
The objective of the present study is to assess differences 
in the competing causes of death in oropharyngeal 
carcinoma (OPC) patients as a function of the HPV status. 
Material and Methods 
We studied retrospectively 423 OPC patients with known 
HPV-status. Among the patients included in the study, 53 
(12.5%) were HPV-positive. We analyzed overall survival 
and competing causes of mortality according to the HPV 
status of the patients. 
Results 
Patients with HPV-negative tumors had lower OPC cancer-
specific survival (P=0.0001), second primary neoplasm 
survival (P=0.0001), and noncancer related causes survival 
(P=0.125) than patients with HPV-positive tumors. This 
resulted in significant differences in overall survival 
depending on HPV status (P=0.0001).  
Conclusion 
HPV-positive OPC have a better overall survival than HPV-
negative OPC. Patients with HPV- positive tumors 
presented a significant lower OPC cancer-specific and 
second primary neoplasm mortality, and a marginally non-
significant lower noncancer mortality as compared to HPV-
negative tumors.
